Hypoxic Ischaemic Encephalopathy Clinical Trial
Official title:
Evaluation of Perinatal Risk Factors for Hypoxic-ischaemic Encephalopathy (HIE) and Their Influence on Severity of Encephalopathy During and After Hypothermia Therapy
The first aim of this study is to analyse perinatal risk factors leading to hypoxic ischaemic
encephalopathy in term and near term neonates born in Switzerland who were admitted to the
neonatal and intensive care units offering hypothermia therapy.
Further, investigators would like to analyse the influence of these perinatal risk factors on
the severity of encephalopathy during and after hypothermia therapy.
Encephalopathy of the neonate could have different aetiologies. Perinatal asphyxia leading to hypoxia-ischaemia is frequent ,1-2 per 1000 life born neonates are affected. Hypoxic ischaemic encephalopathy is one of the most important causes for adverse neurodevelopmental outcome, cerebral palsy, epilepsy and hearing and vision deficiencies in term and near term neonates. Til now, hypothermia therapy is the only therapy reducing the risk of adverse neurodevelopmental outcome and is nowadays standard of care. In this study investigators would like to analyse perinatal risk factors causing HIE and their influence on the Sarnat Score on day 1 and 3 of life (during hypothermia therapy) and on day 4 of life (after hypothermia therapy). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01545271 -
Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth
|
Phase 1/Phase 2 | |
| Completed |
NCT02071394 -
Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth
|
Phase 2 | |
| Completed |
NCT00934700 -
Neuroprotective Effects of Hypothermia Combined With Inhaled Xenon Following Perinatal Asphyxia
|
N/A |